OPKO Health (NASDAQ:OPK) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OPKO Health (NASDAQ:OPK) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has a $3.00 target price on the biotechnology company’s stock.

Several other analysts also recently commented on the stock. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Wednesday.

OPKO Health Stock Down 1.1 %

NASDAQ:OPK opened at $1.78 on Wednesday. The firm’s 50-day moving average price is $1.60 and its 200-day moving average price is $1.56. The company has a market capitalization of $1.20 billion, a PE ratio of -9.37 and a beta of 1.70. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a 1-year low of $0.86 and a 1-year high of $2.04.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. On average, equities analysts predict that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Activity

In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average cost of $1.48 per share, with a total value of $740,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 213,036,477 shares of the company’s stock, valued at approximately $315,293,985.96. This trade represents a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders purchased 889,971 shares of company stock valued at $1,344,442 over the last three months. Insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of OPKO Health by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 8,064 shares during the last quarter. Two Sigma Advisers LP raised its position in OPKO Health by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 8,396 shares during the period. FMR LLC boosted its stake in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 11,089 shares during the last quarter. Comerica Bank grew its position in shares of OPKO Health by 18.2% during the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 16,369 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of OPKO Health by 4.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 18,571 shares in the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.